Phase 1
Redx Pharma dosed its first patient for the Porcupine inhibitor RXC004 on February 6. The company indicates it has paused the trial after the first patient dosed had “clinically significant” adverse events.
Homology Medicines has raised $144 million in an initial public offering of stock.
Analysts look at what else AbbVie has in the pipeline after Rova-T Failure.
A common treatment used to break up the clots and prevent brain damage has become mired in controversy. The treatment, called tissue plasminogen activator (TPA), demonstrated in a clinical trial that the medicine could break up those blood clots and prevent brain damage.
Denali Therapeutics, located in South San Francisco, California, had a lot of news to share today.
A U.S. Food and Drug Administration announced their decision to slap a clinical hold on Solid Biosciences Inc.’s experimental gene therapy treatment for Duchenne muscular dystrophy.
PharmaJet released positive interim results from the U.S. Army’s Phase I clinical trial of two hantavirus vaccines to prevent hemorrhagic fever with renal syndrome (HFRS).
Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.
The FDA placed a hold on Advaxis’ Phase I/II trial following the death of a patient.
Voyager Therapeutics released longer-term data from its ongoing Phase Ib clinical trial of VY-AADC in advanced Parkinson’s disease.
PRESS RELEASES